Paul Tudor Jones Tudor Investment Corp
Paul Tudor Jones is the founder of Tudor Investment Corporation and a pioneering macro trader. He rose to prominence after navigating the 1987 market crash successfully and has since built a multi-strategy firm spanning global markets. Jones is widely associated with discretionary macro trading, risk management discipline, and high-profile philanthropic efforts in education and the environment.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
HZNP
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
|
+$53.9M |
| 2 |
COUP
Coupa Software Incorporated
COUP
|
+$32.1M |
| 3 |
COWN
Cowen Inc. Class A Common Stock
COWN
|
+$27.8M |
| 4 |
Bristol-Myers Squibb
BMY
|
+$20.1M |
| 5 |
M&T Bank
MTB
|
+$20.1M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Y
Alleghany Corp
Y
|
+$93.4M |
| 2 |
BHVN
Biohaven Pharmaceutical Holding Company Ltd.
BHVN
|
+$71.8M |
| 3 |
State Street SPDR S&P 500 ETF Trust
SPY
|
+$42.9M |
| 4 |
ZEN
ZENDESK INC
ZEN
|
+$42.3M |
| 5 |
TWTR
Twitter, Inc.
TWTR
|
+$41.6M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 16.01% |
| 2 | Financials | 11.75% |
| 3 | Industrials | 10.85% |
| 4 | Healthcare | 10.32% |
| 5 | Consumer Discretionary | 8.48% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
1401
Ligand Pharmaceuticals
LGND
$5.59B
| $664K | 0.01% |
+9,944
| New | +$647K |
|
1402
Warby Parker
WRBY
$3.24B
| $663K | 0.01% |
+49,148
| New | +$751K |
|
1403
Target Hospitality
TH
$1.78B
| $662K | 0.01% |
+43,725
| New | +$589K |
|
1404
CALL
Willis Towers Watson
WTW
$32.6B
| $661K | 0.01% |
2,700
+1,400
| +108% | +$320K |
|
|
KDNY
1405
DELISTED
Chinook Therapeutics, Inc. Common Stock
KDNY
| $661K | 0.01% |
25,211
-6,184
| -20% | -$137K |
|
1406
Coupang
CPNG
$29.6B
| $659K | 0.01% |
+44,798
| New | +$791K |
|
|
SWI
1407
DELISTED
SolarWinds Corporation Common Stock
SWI
| $659K | 0.01% |
70,394
-107,989
| -61% | -$943K |
|
|
SBNY
1408
PUT
DELISTED
Signature Bank
SBNY
| $659K | 0.01% |
+5,700
| New | +$783K |
|
|
HTLF
1409
DELISTED
Heartland Financial USA, Inc.
HTLF
| $657K | 0.01% |
+14,099
| New | +$667K |
|
1410
CALL
Cleveland-Cliffs
CLF
$6.45B
| $656K | 0.01% |
40,800
-18,000
| -31% | -$271K |
|
1411
Equinix
EQIX
$104B
| $656K | 0.01% |
+1,002
| New | +$619K |
|
1412
CALL
Johnson & Johnson
JNJ
$658B
| $655K | 0.01% |
3,700
-18,100
| -83% | -$3.13M |
|
1413
Ingersoll Rand
IR
$31B
| $654K | 0.01% |
+12,511
| New | +$639K |
|
1414
Tootsie Roll Industries
TR
$3.11B
| $654K | 0.01% |
17,304
-27,560
| -61% | -$1.01M |
|
1415
PUT
Devon Energy
DVN
$53.1B
| $652K | 0.01% |
+10,600
| New | +$723K |
|
1416
PUT
Tractor Supply
TSCO
$18.7B
| $652K | 0.01% |
+14,500
| New | +$616K |
|
1417
PUT
PepsiCo
PEP
$197B
| $650K | 0.01% |
+3,600
| New | +$642K |
|
1418
Blend Labs
BLND
$355M
| $648K | 0.01% |
449,954
+186,361
| +71% | +$334K |
|
1419
HUB Group
HUBG
$2.46B
| $648K | 0.01% |
+16,300
| New | +$637K |
|
1420
LXP Industrial Trust
LXP
$3.6B
| $648K | 0.01% |
12,941
-3,555
| -22% | -$178K |
|
|
RFP
1421
DELISTED
Resolute Forest Products Inc.
RFP
| $648K | 0.01% |
30,005
-9
| -0% | -$188 |
|
|
MRSH
1422
CALL
Marsh
MRSH
$92.9B
| $645K | 0.01% |
+3,900
| New | +$638K |
|
1423
CALL
Calix
CALX
$2.51B
| $644K | 0.01% |
9,400
+3,700
| +65% | +$249K |
|
1424
PUT
Quest Diagnostics
DGX
$26.9B
| $642K | 0.01% |
+4,100
| New | +$589K |
|
1425
Noble Corp
NE
$7.34B
| $642K | 0.01% |
17,028
+9,825
| +136% | +$349K |
|
Similar funds
Paul Tudor Jones's Q4 2022 Portfolio in Review
As of Q4 2022, Paul Tudor Jones held 3,056 positions worth $5.06B, up 9.2% from $4.63B the previous quarter. Its ten largest holdings account for 9.1% of the portfolio.
Paul Tudor Jones deployed $198M of net new capital in Q4 2022, opening 801 new positions and adding to 766 existing holdings. Its largest new stake was Horizon Therapeutics Public Limited Company Ordinary Shares: 648,672 shares worth $73.8M.
By sector, the portfolio is most concentrated in Technology at 16% of assets, down from 16% a quarter earlier, followed by Financials and Industrials.
On the sell side, the largest reduction was iShares MSCI Emerging Markets ETF, an estimated $39M trimmed.
- Paul Tudor Jones's largest Q4 2022 buy was Horizon Therapeutics Public Limited Company Ordinary Shares: 648,672 shares worth $73.8M.
- Paul Tudor Jones added most to Coupa Software Incorporated in Q4 2022, an estimated $32.1M increase.
- Paul Tudor Jones's biggest Q4 2022 reduction was iShares MSCI Emerging Markets ETF, cutting an estimated $39M.
- Paul Tudor Jones fully exited Alleghany Corp in Q4 2022, selling an estimated $93.4M.
- Paul Tudor Jones's ten largest holdings make up 9.1% of its $5.06B portfolio in Q4 2022.
- Paul Tudor Jones opened 801 new positions and closed 756 in Q4 2022.
- Paul Tudor Jones's portfolio value rose 9.2% quarter-over-quarter to $5.06B.
Based on Tudor Investment Corp's 13F filing for Q4 2022, filed 14 Feb 2023.